AstraZeneca (STU:ZEGA) Short Ratio

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:ZEGA AstraZeneca PLC STU:ZEGA
88 GF Score
Price €78.00
GF Value €82.55
! 1 Warning Sign
View Full Analysis

What is AstraZeneca Short Ratio?

Short Ratio is a metric signaling prevailing investors' sentiment with a company. It represents the number of days it takes short sellers on average to repurchase all the shares short.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

STU:ZEGA
88GF Score
AstraZeneca PLC STU:ZEGA
Short Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is AstraZeneca (STU:ZEGA) Overvalued in 2026?

Based on GuruFocus' analysis, AstraZeneca stock appears to be undervalued. The current stock price of €78.00 is trading 5.5% below its estimated GF Value™ of €82.55.

Key valuation signals for STU:ZEGA:

  • Short Ratio:
  • GF Value™: €82.55 vs. price of €78.00 (5.5% below fair value)
  • GF Score™: 88/100 with 1 warning sign

No single metric tells the full story. See the STU:ZEGA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


AstraZeneca Business Description

Address 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, GBR, CB2 0AA
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.
88GF Score

Get the complete analysis for STU:ZEGA

Short Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€78.00
Price
€82.55
GF Value